Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATPharm: Pharmacy-based vs Usual Care MAT for OUD
NCT04139213Phase 3Unknown
- Sponsor
- Lifespan Biotech
- Start
- Jul 2019
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Lifespan Biotech. Primary endpoints: Retention in Medication Assisted Treatment at 90 days and Relapse to drug use at 90 days. Status: unknown.
Beyond the preview
Go deeper on NCT04139213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139213.